Central composite rotatable design for optimization of budesonide-loaded cross-linked chitosan–dextran sulfate nanodispersion: characterization, in vitro diffusion and aerodynamic study

References

• Beck-Broichsitter M, Kleimann P, Gessler T, et al. Nebulization performance of biodegradable sildenafil-loaded nanoparticles using the Aeroneb Pro: formulation aspects and nanoparticle stability to nebulization. Int J Pharm. 2012;422:398–408.
   PubMed Web of Science ®Google Scholar
• Kollipara S, Bende G, Movva S, et al. Application of rotatable central composite design in the preparation and optimization of poly (lactic-co-glycolic acid) nanoparticles for controlled delivery of paclitaxel. Drug Dev Ind Pharm. 2010;36:1377–1387.
   PubMed Web of Science ®Google Scholar
• Quintanar-Guerrero D, Allémann E, Fessi H, et al. (1998) Preparation techniques and mechanisms of formation of biodegradable nanoparticles from preformed polymers. Drug Dev Ind Pharm. 1998;24:1113–1128.
   PubMed Web of Science ®Google Scholar
• Amani A, Amini MA, Ali HS, et al. Alternatives to conventional suspensions for pulmonary drug delivery by nebulisers: a review. J Pharm Sci. 2011;100:4563–4570.
   PubMed Web of Science ®Google Scholar
• Xiang QY, Wang MT, Chen F, et al. Lung-targeting delivery of dexamethasone acetate loaded solid lipid nanoparticles. Arch Pharm Res. 2007;30:519–525.
   PubMed Web of Science ®Google Scholar
• Deacon J, Abdelghany SM, Quinn DJ, et al. Antimicrobial efficacy of tobramycin polymeric nanoparticles for Pseudomonas aeruginosa infections in cystic fibrosis: formulation, characterisation and functionalisation with dornase alfa (DNase). J Control Release. 2015;198:5–61.
   Web of Science ®Google Scholar
• Smola M, Vandamme T, Sokolowski A. Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and nonrespiratory diseases. Int J Nanomedicine. 2008;3:1–9.
   PubMed Web of Science ®Google Scholar
• Byron PR, Patton JS. Drug delivery via the respiratory tract. J Aerosol Med. 1994;7:49–75.
   PubMedGoogle Scholar
• Yang W, Peters JI, Williams RO. Inhaled nanoparticles—a current review. Int J Pharm. 2008;356:239–247.
   PubMed Web of Science ®Google Scholar
• Groneberg DA, Witt C, Wagner U, et al. Fundamentals of pulmonary drug delivery. Respir Med. 2003;97:382–387.
   PubMed Web of Science ®Google Scholar
• Lourenço RV, Cotromanes E. Clinical aerosols. I. Characterization of aerosols and their diagnostic uses. Arch Intern Med. 1982;142:2163–2172.
   PubMed Web of Science ®Google Scholar
• Carvalho TC, Peters JI, Williams RO. Influence of particle size on regional lung deposition—what evidence is there? Int J Pharm. 2011;406:1–10.
   PubMed Web of Science ®Google Scholar
• Van Rijt SH, Bein T, Meiners S. Medical nanoparticles for next generation drug delivery to the lungs. Eur Respir J. 2014;44:765–774.
   PubMed Web of Science ®Google Scholar
• El‐Gendy N, Gorman EM, Munson EJ, et al. Budesonide nanoparticle agglomerates as dry powder aerosols with rapid dissolution. J Pharm Sci. 2008;98:2731–2746.
   Web of Science ®Google Scholar
• Ali ME, McConville JT, Lamprecht A. Pulmonary delivery of anti-inflammatory agents. Expert Opin Drug Deliv. 2015;12:929–945.
   PubMed Web of Science ®Google Scholar
• Pilcer G, Vanderbist F, Amighi K. Preparation and characterization of spray-dried tobramycin powders containing nanoparticles for pulmonary delivery. Int J Pharm. 2009;365:162–169.
   PubMed Web of Science ®Google Scholar
• Letchford K, Burt H. A review of the formation and classification of amphiphilic block copolymer nanoparticulate structures: micelles, nanospheres, nanocapsules and polymersomes. Eur J Pharm Biopharm. 2007;65:259–269.
   PubMed Web of Science ®Google Scholar
• Vauthier C, Bouchemal K. Methods for the preparation and manufacture of polymeric nanoparticles. Pharm Res. 2009;26:1025–1058.
   PubMed Web of Science ®Google Scholar
• Ghosh I, Bose S, Vippagunta R, et al. Nanosuspension for improving the bioavailability of a poorly soluble drug and screening of stabilizing agents to inhibit crystal growth. Int J Pharm. 2011;409:260–268.
   PubMed Web of Science ®Google Scholar
• Bandi N, Wei W, Roberts CB, et al. Preparation of Budesonide and indomethacin–hydroxypropyl-β-cyclodextrin (HPBCD) complexes using a single-step, organic-solvent-free supercritical fluid process. Eur J Pharm Sci. 2004;23:159–168.
   PubMed Web of Science ®Google Scholar
• Keshavarzian A, Farhadi A, Mutlu EA. New developments in the treatment of inflammatory bowel disease. Expert Opin Investig Drugs. 2002;11:365–385.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. The role of inflammation and anti-inflammatory medication in asthma. Respir Med. 2002;96:S9–S15.
   PubMed Web of Science ®Google Scholar
• Sirand C, Hickey AJ, Varlet JP. Aerosol-filling equipment for the preparation of pressurized-pack pharmaceutical formulations. In: Hickey AJ, editor. Pharmaceutical inhalation aerosol technology. 2nd ed. New York: Marcel Dekker; 2003. p. 311–343.
   Google Scholar
• Xu Z, Mansour HM, Mulder T, et al. Heterogeneous particle deaggregation and its implication for therapeutic aerosol performance. J Pharm Sci. 2010;99:3442–3461.
   PubMed Web of Science ®Google Scholar
• Mizgerd JP. Acute lower respiratory tract infection. N Engl J Med. 2008;358:716–727.
   PubMed Web of Science ®Google Scholar
• Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B: Biointerfaces. 2010;75:1–18.
   PubMed Web of Science ®Google Scholar
• Bhatt H, Naik B, Dharamsi A. Solubility enhancement of budesonide and statistical optimization of coating variables for targeted drug delivery. J Pharm. 2014;1–13.
   Google Scholar
• Naikwade SR, Bajaj AN, Gurav P, et al. Development of budesonide microparticles using spray-drying technology for pulmonary administration: design, characterization, in vitro evaluation, and in vivo efficacy study. AAPS PharmSciTech. 2009;10:993–1012.
   PubMed Web of Science ®Google Scholar
• Van der Velden VHJ. Glucocorticoids: mechanisms of action and anti-inflammatory potential in asthma. Mediators Inflamm. 1998;7:229–237.
   PubMed Web of Science ®Google Scholar
• Swierczewska M, Han HS, Kim K, et al. Polysaccharide-based nanoparticles for theranostic nanomedicine. Adv Drug Deliv Rev. 2016;99:70–84.
   PubMed Web of Science ®Google Scholar
• Rytting E, Nguyen J, Wang X, et al. Biodegradable polymeric nanocarriers for pulmonary drug delivery. Expert Opin Drug Deliv. 2008;5:629–639.
   PubMed Web of Science ®Google Scholar
• Muller RH, Becker R, Kruss B, et al. Medac Gesellschaft Fur Klinische Spezialpraparate, Pharmaceutical nanosuspensions for medicament administration as systems with increased saturation solubility and rate of solution. U.S. patent 5,858,410. 1999.
   Google Scholar
• Ponchel G, Montisci MJ, Dembri A, et al. Mucoadhesion of colloidal particulate systems in the gastro-intestinal tract. Eur J Pharm Biopharm. 1997;44:25–31.
   Web of Science ®Google Scholar
• Jacobs C, Müller RH. Production and characterization of a budesonide nanosuspension for pulmonary administration. Pharm Res. 2002;19:189–194.
   PubMed Web of Science ®Google Scholar
• Zhao YX, Hua HY, Chang M, et al. Preparation and cytotoxic activity of hydroxyl camptothecin nanosuspensions. Int J Pharm. 2010;392:64–71.
   PubMed Web of Science ®Google Scholar
• Nasr M, Taha I, Hathout RM. Suitability of liposomal carriers for systemic delivery of risedronate using the pulmonary route. Drug Deliv. 2013;20:311–318.
   PubMed Web of Science ®Google Scholar
• Kompella UB, Bandi N, Ayalasomayajula SP. Subconjunctival nano-and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression. Invest Ophthalmol Vis Sci. 2003;44:1192–1201.
   PubMed Web of Science ®Google Scholar
• Tamjidi F, Shahedi M, Varshosaz J, et al. EDTA and α‐tocopherol improve the chemical stability of astaxanthin loaded into nanostructured lipid carriers. Eur J Lipid Sci Technol. 2014;116:968–977.
   Web of Science ®Google Scholar
• Sarmento B, Ribeiro A, Veiga F, et al. Development and characterization of new insulin containing polysaccharide nanoparticles. Colloids Surf B. 2006;53:193–202.
   PubMed Web of Science ®Google Scholar
• Souto EB, Wissing SA, Barbosa CM, et al. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int J Pharm. 2004;278:71–77.
   PubMed Web of Science ®Google Scholar
• Hickey AJ. Summary of common approaches to pharmaceutical aerosol administration. In: Hickey AJ, editors. Pharmaceutical inhalation aerosol technology. 2nd ed. New York: Marcel Dekker, Inc.; 2003. p. 385–421.
   Google Scholar
• Shete H, Patravale V. Long chain lipid based tamoxifen NLC. Part I: preformulation studies, formulation development and physicochemical characterization. Int J Pharm. 2013;454:573–583.
   PubMed Web of Science ®Google Scholar
• Kotze AF, Luessen HL. Chitosan: bioadhesive drug delivery system, fundamentals, novel approaches and development. In: Mathiowitz DE, editor. Drug and pharmaceutical sciences. 2nd ed. Vol. 98. New York: Marcel Dekker, Inc.; 2003. p. 341–386.
   Google Scholar
• Paranjpe M, Müller-Goymann CC. Nanoparticle-mediated pulmonary drug delivery: a review. Int J Mol Sci. 2014;15:5852–5859.
   PubMed Web of Science ®Google Scholar
• Ostrander KD, Bosch WH, Bondan M. An in-vitro assessment of a nano crystal beclomethasone dipropionate colloidal dispersion via ultrasonic nebulization. Eur J Pharm Biopharm. 1999;48:207–215.
   PubMed Web of Science ®Google Scholar
• Zhang X, Liu Q, Hu J, et al. An aerosol formulation of R-salbutamol sulfate for pulmonary inhalation. Acta Pharm Sin B. 2014;4:79–85.
   PubMed Web of Science ®Google Scholar
• Ige PP, Baria RK, Gattani SG. Fabrication of fenofibrate nanocrystals by probe sonication method for enhancement of dissolution rate and oral bioavailability. Colloids Surf B Biointerfaces. 2013;108:366–373.
   PubMed Web of Science ®Google Scholar
• Anitha A, Deepagan VG, Rani VD, et al. Preparation, characterization, in vitro drug release and biological studies of curcumin loaded dextran sulfate–chitosan nanoparticles. Carbohydr Polym. 2011;84:1158–1164.
   Web of Science ®Google Scholar
• Dinda A, Biswal I, Das D, et al. Effect of stabilizers and process parameters for budesonide loaded PLGA-nanoparticles. Int J Drug Deliv. 2011;3:371.
   Google Scholar
• Muthu MS, Feng SS. Pharmaceutical stability aspects of nanomedicines. Nanomedicine (London). 2009;4:857–860.
   PubMed Web of Science ®Google Scholar
• Ige PP, Rajput P, Pardeshi C, et al. Development of pellets of nifedipine using HPMC K15 M and κ-carrageenan as mucoadhesive sustained delivery system and in vitro evaluation. Iran Polym J. 2013;22:911–921.
   Web of Science ®Google Scholar
• Yang JZ, Young AL, Chiang P-C, et al. Fluticasone and budesonide nanosuspensions for pulmonary delivery: preparation, characterization, and pharmacokinetic studies. J Pharm Sci. 2008;97:4869–4878.
   PubMed Web of Science ®Google Scholar
• Kulkarni AD, Vanjari YH, Sancheti KH, et al. New nasal noncomplex self assembled from charged biomacromolecules: N, N, N-trimethyl chitosan and dextran sulfate. Int J Biomacromol. 2016;88:476–490.
   PubMed Web of Science ®Google Scholar
• Kean T, Thanou M. Biodegradation, biodistribution and toxicity of chitosan. Adv Drug Deliv Rev. 2010;62:3–11.
   PubMed Web of Science ®Google Scholar